Annexon (ANNX) reported second-quarter 2026 financial results and portfolio updates, including a net loss attributable to common stockholders of $55.3 million, or $0.28 per share, for the quarter ended June 30, 2026.
Cash, cash equivalents and short-term investments were $209.2 million as of June 30, 2026. The company said its current funds and proceeds from a new credit facility are expected to fund operations and anticipated milestones into 2028.
- Cash position Cash, cash equivalents and short-term investments totaled $209.2 million as of June 30, 2026.
- Credit facility Annexon entered a strategic credit facility of up to $200 million with Oxford Finance LLC, with an initial $50 million drawn at closing.
- R&D expenses Research and development expenses were $46.6 million for the quarter, compared with $44.2 million a year earlier.
- G&A expenses General and administrative expenses were $10.6 million, compared with $7.6 million a year earlier.
- Tanruprubart The company expects a Biologics License Application submission with U.S. and European data from the FORWARD trial in the fourth quarter of 2026.
- Vonaprument The Month 15 primary endpoint remains on track for the fourth quarter of 2026, with final trial completion including the Month 24 endpoint expected in the third quarter of 2027.
- ANX1502 Annexon expects an update on proof-of-concept data in cold agglutinin disease in fall 2026.
$ANNX Insider Trading Activity
$ANNX insiders have traded $ANNX stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ANNX stock by insiders over the last 6 months:
- MUNEER A SATTER purchased 613,497 shares for an estimated $3,319,018
- WILLIAM H. CARSON has made 3 purchases buying 24,000 shares for an estimated $141,200 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ANNX Hedge Fund Activity
We have seen 121 institutional investors add shares of $ANNX stock to their portfolio, and 82 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REDMILE GROUP, LLC added 4,499,124 shares (+44.8%) to their portfolio in Q1 2026, for an estimated $24,925,146
- SIREN, L.L.C. added 3,958,646 shares (+inf%) to their portfolio in Q1 2026, for an estimated $21,930,898
- STATE STREET CORP added 2,905,066 shares (+42.0%) to their portfolio in Q2 2026, for an estimated $16,587,926
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,800,000 shares (+186.7%) to their portfolio in Q1 2026, for an estimated $15,512,000
- BANK OF AMERICA CORP /DE/ added 2,654,414 shares (+165.3%) to their portfolio in Q1 2026, for an estimated $14,705,453
- BLACKROCK, INC. added 2,601,235 shares (+23.8%) to their portfolio in Q2 2026, for an estimated $14,853,051
- LONGAEVA PARTNERS L.P. removed 2,479,599 shares (-80.0%) from their portfolio in Q1 2026, for an estimated $13,736,978
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
